EGFR and head and neck squamous cell carcinoma: Motolimod was demonstrated to augment clinical responses in patients with HNSCC of advanced stages, who have also been treated with the epidermal growth factor receptor inhibitor cetuximab (phase I trial NCT01334177) (209).